Literature DB >> 11353564

A perspective on inflammatory bowel disease in the child and adolescent at the turn of the millennium.

C Haller1, J Markowitz.   

Abstract

The literature of the past year has produced significant advances relevant to the diagnosis and treatment of children and adolescents with inflammatory bowel disease. This review focuses on new observations regarding the epidemiology, genetics, etiology, diagnosis, and treatment of both Crohn's disease and ulcerative colitis in children. Particular attention is paid to the expanded indications for the use of immunomodulatory therapy, and to the early published data regarding the safety and efficacy of treatment with infliximab.

Entities:  

Mesh:

Year:  2001        PMID: 11353564     DOI: 10.1007/s11894-001-0031-6

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  36 in total

1.  Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity.

Authors:  S R Brant; C I Panhuysen; J E Bailey-Wilson; P M Rohal; S Lee; J Mann; G Ravenhill; B S Kirschner; S B Hanauer; J H Cho; T M Bayless
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

2.  Introduction of 6-mercaptopurine in Crohn's disease patients during the perioperative period: a preliminary evaluation of recurrence of disease.

Authors:  H A Kader; S C Raynor; R Young; S S Kaufman; J Vanderhoof; E I Ruby; D R Mack
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-07       Impact factor: 2.839

3.  Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.

Authors:  S Kugathasan; S L Werlin; A Martinez; M T Rivera; J B Heikenen; D G Binion
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

4.  Colonoscopy and technetium-99m white cell scan in children with suspected inflammatory bowel disease.

Authors:  S Cucchiara; L Celentano; T M de Magistris; A Montisci; V D Iula; S Fecarotta
Journal:  J Pediatr       Date:  1999-12       Impact factor: 4.406

5.  Crohn's disease and cancer risk (Denmark).

Authors:  L Mellemkjaer; C Johansen; G Gridley; M S Linet; S K Kjaer; J H Olsen
Journal:  Cancer Causes Control       Date:  2000-02       Impact factor: 2.506

6.  Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.

Authors:  P S Kim; J Zlatanic; B I Korelitz; G W Gleim
Journal:  Am J Gastroenterol       Date:  1999-11       Impact factor: 10.864

7.  Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease.

Authors:  M Orholm; K Fonager; H T Sørensen
Journal:  Am J Gastroenterol       Date:  1999-11       Impact factor: 10.864

8.  Early measles virus infection is associated with the development of inflammatory bowel disease.

Authors:  D S Pardi; W J Tremaine; W J Sandborn; E V Loftus; G A Poland; W S Harmsen; A R Zinsmeister; L J Melton
Journal:  Am J Gastroenterol       Date:  2000-06       Impact factor: 10.864

9.  Magnetic resonance imaging to distinguish the type and severity of pediatric inflammatory bowel diseases.

Authors:  C A Durno; P Sherman; T Williams; B Shuckett; A Dupuis; A M Griffiths
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-02       Impact factor: 2.839

10.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

Authors:  Y Bouhnik; M Lémann; J Y Mary; G Scemama; R Taï; C Matuchansky; R Modigliani; J C Rambaud
Journal:  Lancet       Date:  1996-01-27       Impact factor: 79.321

View more
  2 in total

1.  Manometric study in ulcerative colitis patients with modified ileal pouch--anal anastomosis.

Authors:  Georgi Kobakov; Daniel Kostov; Temelko Temelkov
Journal:  Int J Colorectal Dis       Date:  2006-04-01       Impact factor: 2.571

2.  Human inflammatory bowel disease does not associate with Lawsonia intracellularis infection.

Authors:  Christoph W Michalski; Fabio Francesco Di Mola; Klaus Kümmel; Michael Wendt; Jörg S Köninger; Thomas Giese; Nathalia A Giese; Helmut Friess
Journal:  BMC Microbiol       Date:  2006-09-19       Impact factor: 3.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.